TrialBreast cancer research and treatment2023

Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer.

Caitlin Taylor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.